Enthera Overview
- Founded
-
2016

- Status
-
Private
- Employees
-
15

- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$42.6M
- Investors
-
9
Enthera General Information
Description
Developer of biotherapeutics intended to treat auto-immune disorders. The company's pipelined products target pathways involved in cell apoptosis in the gut, pancreas, and other organs which plays a key role in the development of type 1 diabetes and inflammatory bowel disease, enabling the medical community to effectively combat intractable autoimmune diseases.
Contact Information
Website
www.entherapharmaceuticals.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- Via Gioberti, 8
- 20123 Milan(Lombardy)
- Italy
+39 02 0000 0000
Enthera Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Later Stage VC (Series A) | 28-Jan-2021 | $42.6M | 000.00 | Completed | Pre-Clinical Trials | |
3. Seed Round | 24-Jul-2018 | 00.000 | 00.000 | Completed | Pre-Clinical Trials | |
2. Early Stage VC | 10-May-2018 | Completed | Pre-Clinical Trials | |||
1. Seed Round | 01-Oct-2016 | Completed | Pre-Clinical Trials |
Enthera Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Developer of biotherapeutics intended to treat auto-immune disorders. The company's pipelined products target pathways i
Drug Discovery
Milan, Italy
15
As of 2022
000.00
00000000000
000.00
Enthera Competitors (32)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
AnTolRx | Venture Capital-Backed | Cambridge, MA | 000 | 00000000000 | 000 | |
000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 0 | 00000 | 000000&0 | 00000 |
0000000 0000000000 | Private Equity-Backed | Needham, MA | 00 | 00000 | 000000000000 | 00000 |
00000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 000000&0 | |
0000000 0000000000 | Formerly VC-backed | Burlington, MA | 0 | 00000 | 000000000 | 00000 |
Enthera Patents
Enthera Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2021225061-A1 | Inhibitors and uses thereof | Pending | 20-Feb-2020 | 000000000 | |
CA-3162043-A1 | Inhibitors and uses thereof | Pending | 20-Feb-2020 | 000000000 | |
EP-3868396-A1 | Inhibitors and uses thereof | Inactive | 20-Feb-2020 | 000000000 | |
EP-4106804-A1 | Inhibitors and uses thereof | Pending | 20-Feb-2020 | 000000000 | |
CA-3154017-A1 | Igfbp3 antibodies and therapeutic uses thereof | Pending | 21-Nov-2019 | C07K16/18 |
Enthera Executive Team (8)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Aled Williams | Chief Executive Officer & Board Member | ||
Lucia Reggi | Financial Director | ||
Francesca D'Addio Ph.D | Co-Founder & Head of Preclinical Research | ||
Silvano Spinelli | Co-Founder & Chairman | ||
Antonio Speziale | Chief Medical Officer |
Enthera Board Members (11)
Name | Representing | Role | Since |
---|---|---|---|
Aled Williams | Enthera | Chief Executive Officer & Board Member | 000 0000 |
Anta Gkelou Ph.D | Sofinnova Partners | Board Observer | 000 0000 |
Carole Nuechterlein JD | Roche Venture Fund | Board Member | 000 0000 |
Graziano Seghezzi | Sofinnova Partners | Board Member | 000 0000 |
Katie Elias | Self | Board Observer | 000 0000 |
Enthera Signals
Enthera Investors (9)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
AbbVie Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
Banca Profilo | PE-Backed Company | Minority | 000 0000 | 000000 0 | |
Banor Sim | Asset Manager | Minority | 000 0000 | 000000 0 | |
Roche Venture Fund | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
Juvenile Diabetes Research Foundation | Limited Partner | Minority | 000 0000 | 000000 0 |